CoChat
Sign Up
Cited by 144

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Proteasome Activation by Small Molecules

Leestemaker, Yves, de Jong, Annemieke, Witting, Katharina F., Penning, Renske, Schuurman, Karianne, Rodenko, Boris, Zaal, Esther A., van de Kooij, Bert, Laufer, Stefan, Heck, Albert J.R., Borst, Jannie, Scheper, Wiep, Berkers, Celia R., Ovaa, Huib·2017·Cell Chemical Biology
DOI 10.1016/j.chembiol.2017.05.010
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2017.05.010

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 50

  1. Abelin, 2016, Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes, Mol. Cell Proteomics, 15, 1622, 10.1074/mcp.M116.058354 · DOI
  2. Al-Ramahi, 2006, CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation, J. Biol. Chem., 281, 26714, 10.1074/jbc.M601603200 · DOI
  3. Anderson, 2007, Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2), J. Med. Chem., 50, 2647, 10.1021/jm0611004 · DOI
  4. Asai, 2009, PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts, J. Mol. Cell Cardiol., 46, 452, 10.1016/j.yjmcc.2008.11.001 · DOI
  5. Atzori, 2001, Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis, J. Neuropathol. Exp. Neurol., 60, 1190, 10.1093/jnen/60.12.1190 · DOI
  6. Avitzour, 2007, Intrinsically active variants of all human p38 isoforms, FEBS J., 274, 963, 10.1111/j.1742-4658.2007.05644.x · DOI
  7. Bendotti, 2004, Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice, J. Neuropathol. Exp. Neurol., 63, 113, 10.1093/jnen/63.2.113 · DOI
  8. Benjamini, 1995, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J. R. Stat. Soc. Ser. B (Methodological), 57, 289, 10.1111/j.2517-6161.1995.tb02031.x · DOI · Paper page
  9. Berkers, 2005, Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib, Nat. Methods, 2, 357, 10.1038/nmeth759 · DOI
  10. Berkers, 2007, Profiling proteasome activity in tissue with fluorescent probes, Mol. Pharm., 4, 739, 10.1021/mp0700256 · DOI · Paper page
  11. Borst, 2013, Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation, Cell Physiol. Biochem., 31, 914, 10.1159/000350110 · DOI
  12. Dahlmann, 2000, Different proteasome subtypes in a single tissue exhibit different enzymatic properties, J. Mol. Biol., 303, 643, 10.1006/jmbi.2000.4185 · DOI
  13. Dantuma, 2014, The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution, Front. Mol. Neurosci., 7, 70, 10.3389/fnmol.2014.00070 · DOI
  14. Dantuma, 2000, Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells, Nat. Biotechnol., 18, 538, 10.1038/75406 · DOI · Paper page
  15. de Jong, 2012, Fluorescence-based proteasome activity profiling, Methods Mol. Biol., 803, 183, 10.1007/978-1-61779-364-6_13 · DOI
  16. de Wit, 2009, Matrix-dependent local retention of secretory vesicle cargo in cortical neurons, J. Neurosci., 29, 23, 10.1523/JNEUROSCI.3931-08.2009 · DOI
  17. Ebrahimi-Fakhari, 2011, Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein, J. Neurosci., 31, 14508, 10.1523/JNEUROSCI.1560-11.2011 · DOI
  18. Glickman, 2002, The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction, Physiol. Rev., 82, 373, 10.1152/physrev.00027.2001 · DOI
  19. Guo, 2015, Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis, Nat. Cell Biol., 18, 202, 10.1038/ncb3289 · DOI · Paper page
  20. Heubner, 2011, The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer, Gynecol. Oncol., 120, 233, 10.1016/j.ygyno.2010.10.014 · DOI
  21. Hideshima, 2001, The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, Cancer Res., 61, 3071
  22. Kim, 2010, Pathological roles of MAPK signaling pathways in human diseases, Biochim. Biophys. Acta, 1802, 396, 10.1016/j.bbadis.2009.12.009 · DOI · Paper page
  23. Kniepert, 2014, The unique functions of tissue-specific proteasomes, Trends Biochem. Sci., 39, 17, 10.1016/j.tibs.2013.10.004 · DOI
  24. Koeberle, 2012, Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor, Nat. Chem. Biol., 8, 141, 10.1038/nchembio.761 · DOI
  25. Köhler, 2001, The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release, Mol. Cell, 7, 1143, 10.1016/S1097-2765(01)00274-X · DOI
  26. Kristiansen, 2007, Disease-associated prion protein oligomers inhibit the 26S proteasome, Mol. Cell, 26, 175, 10.1016/j.molcel.2007.04.001 · DOI
  27. Lee, 2009, The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease, J. Neurochem., 110, 208, 10.1111/j.1471-4159.2009.06124.x · DOI
  28. Lee, 2010, Enhancement of proteasome activity by a small-molecule inhibitor of USP14, Nature, 467, 179, 10.1038/nature09299 · DOI · Paper page
  29. Lee, 2010, Osmotic stress inhibits proteasome by p38 MAPK-dependent phosphorylation, J. Biol. Chem., 285, 41280, 10.1074/jbc.M110.182188 · DOI
  30. Li, 2004, Stabilization of alpha-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation, J. Neurosci., 24, 7400, 10.1523/JNEUROSCI.1370-04.2004 · DOI
  31. Li, 2009, Variably modulated gating of the 26S proteasome by ATP and polyubiquitin, Biochem. J., 421, 397, 10.1042/BJ20090528 · DOI
  32. Lin, 2013, Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease, Mol. Cell Biol., 33, 1073, 10.1128/MCB.01434-12 · DOI · Paper page
  33. Liu, 2014, Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease, J. Neurochem., 129, 539, 10.1111/jnc.12647 · DOI
  34. Lokireddy, 2015, cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins, Proc. Natl. Acad. Sci. USA, 112, E7176, 10.1073/pnas.1522332112 · DOI · Paper page
  35. Myeku, 2016, Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling, Nat. Med., 22, 46, 10.1038/nm.4011 · DOI · Paper page
  36. Outeiro, 2008, Formation of toxic oligomeric alpha-synuclein species in living cells, PLoS One, 3, e1867, 10.1371/journal.pone.0001867 · DOI
  37. Pelletier, 2010, Quantifying cross-tissue diversity in proteasome complexes by mass spectrometry, Mol. Biosyst., 6, 1450, 10.1039/c004989a · DOI
  38. Perrotton, 2007, (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1, J. Biol. Chem., 282, 31542, 10.1074/jbc.M703964200 · DOI
  39. Peth, 2009, Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening, Mol. Cell, 36, 794, 10.1016/j.molcel.2009.11.015 · DOI
  40. Ross, 2000, Systematic variation in gene expression patterns in human cancer cell lines, Nat. Genet., 24, 227, 10.1038/73432 · DOI · Paper page
  41. Sakamoto, 2001, Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation, Proc. Natl. Acad. Sci. USA, 98, 8554, 10.1073/pnas.141230798 · DOI · Paper page
  42. Snyder, 2003, Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function, J. Biol. Chem., 278, 11753, 10.1074/jbc.M208641200 · DOI
  43. Tortarolo, 2003, Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression, Mol. Cell Neurosci., 23, 180, 10.1016/S1044-7431(03)00022-8 · DOI
  44. Tsai, 2003, Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function, J. Biol. Chem., 278, 22044, 10.1074/jbc.M212235200 · DOI
  45. Tyanova, 2016, The Perseus computational platform for comprehensive analysis of (prote)omics data, Nat. Methods, 13, 731, 10.1038/nmeth.3901 · DOI · Paper page
  46. Um, 2010, ASK1 negatively regulates the 26 S proteasome, J. Biol. Chem., 285, 36434, 10.1074/jbc.M110.133777 · DOI
  47. Wang, 2007, Mass spectrometric characterization of the affinity-purified human 26S proteasome complex, Biochemistry, 46, 3553, 10.1021/bi061994u · DOI · Paper page
  48. Zhang, 2007, Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6, J. Biol. Chem., 282, 22460, 10.1074/jbc.M702439200 · DOI
  49. Zhou, 2013, Robust phosphoproteome enrichment using monodisperse microsphere-based immobilized titanium (IV) ion affinity chromatography, Nat. Protoc., 8, 461, 10.1038/nprot.2013.010 · DOI
  50. Zhu, 2000, Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease, J. Neuropathol. Exp. Neurol., 59, 880, 10.1093/jnen/59.10.880 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Leestemaker, Y., de Jong, A., Witting, K. F., Penning, R., Schuurman, K., Rodenko, B., Zaal, E. A., van de Kooij, B., Laufer, S., Heck, A. J. R., Borst, J., Scheper, W., Berkers, C. R., & Ovaa, H.
Venue
Cell Chemical Biology
Publisher
Elsevier BV
Published
2017-06
Volume
24
Issue
6
Pages
725-736.e7
ISSN
2451-9456
DOI
10.1016/j.chembiol.2017.05.010
Cited by
144
References
3
Language
en
Licence
Funders
Netherlands Organisation for Scientific Research (724.013.002, 722.013.009, 184.032.201)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review